Pancreatic Cancer
Conditions
Keywords
Pancreatic cancer, Biomarker, chemotherapy, pharmacogenomic, clinical trials
Brief summary
1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center. 2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center
Detailed description
1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample 2. Collect data of Biomarker for pancreatic cancer 3. Compare with Big data and Cohort study in National cancer center 4. The number of subjects is changed by statistical consideration. 218-\>238
Interventions
None listed
Sponsors
National Cancer Center, Korea
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Pathologically Confirmed Pancreatic Cancer Patients
Exclusion criteria
* Subjects who do not agree with the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| median survival | 5 years | The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse |
| progressive-free survival | 5 years | The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse |
Countries
South Korea
Outcome results
None listed